Hepcidins as Biomarkers for Impending Lupus Nephritis Flare
AssigneeThe Ohio State University
InventorsBrad H. Rovin, Xiaolan Zhang
Life of this patent
Estimating the term…
Abstract
Biomarkers for determining a kidney flare episode in systemic lupus erythematosus are described.
Claims23
A method for assigning a therapy regimen and/or assigning a prognosis to a subject diagnosed with or suspected of suffering from systemic lupus erythematosus, comprising:
- assaying at least one urine sample obtained from the subject to provide one or more detectable signals related to the presence or amount of one or more subject-derived hepcidin-20 and hepcidin-25 biomarkers;
- and
- correlating the one or more signals obtained from the assaying step to ruling in or out a therapy regimen for the subject, and/or assigning a prognosis to the subject.
A method for diagnosing a disease condition characterized by non-physiological levels of hepcidin, comprising:
- obtaining a urine sample from a subject;
- contacting the urine sample with an antibody or fragment thereof that specifically binds to one or more binding sites on hepcidin, and
- quantifying hepcidin level in the urine sample;
- wherein the non-physiological level of hepcidin is indicative of the disease condition.
A kit for detecting a disease condition characterized by non-physiological levels of hepcidin, comprising:
- at least one anti-hepcidin antibody or fragment thereof that specifically binds to one or more mid-portion or carboxy terminal epitopes of hepcidin, and
- at least one reagent that binds directly or indirectly to the antibody or fragment thereof.
The kit of claim 20, wherein the anti-hepcidin antibody or fragment thereof is immobilized on a support.
A test device for performing a method of analyzing a subject sample for one or more subject-derived hepcidin-20 and hepcidin-25 biomarker selected to identify at least a beginning of a kidney flare episode in a patient suffering from systemic lupus erythematosus (SLE), the test device comprising:
- a test surface comprising a plurality of discrete addressable locations corresponding to hepcidin-20 and hepcidin-25 biomarkers,
- each the location comprising an antibody immobilized at the location selected to bind for detection one of the hepcidin-20 and hepcidin-25 biomarkers.
Dependencies are inferred from the claim text.